<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30400">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710955</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01-SWAN</org_study_id>
    <nct_id>NCT02710955</nct_id>
  </id_info>
  <brief_title>SWAN: Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)</brief_title>
  <acronym>SWAN</acronym>
  <official_title>Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of a new thickened formula on
      regurgitation
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of episodes of regurgitation per day</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regurgitation score assessed through Vandenplas score</measure>
    <time_frame>14 and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stools frequency over 72h</measure>
    <time_frame>14 and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stools consistency assessed through Bristol Stool form Scale</measure>
    <time_frame>14 and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight expressed in z scores according to the WHO Child Growth Standards</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height expressed in z scores according to the WHO Child Growth Standards</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI expressed in z scores according to the WHO Child Growth Standards</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head circumference expressed in z scores according to the WHO Child Growth Standards</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Thickened infant formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Thickened infant formula</intervention_name>
    <arm_group_label>Thickened infant formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants :

               -  Aged â‰¤ 5 months old

               -  fully formula fed

               -  with at least 5 episodes of regurgitation per day, for at least a week

        Exclusion Criteria:

          -  Breast fed infants

          -  Infants presenting symptoms of a complicated gastroesophageal reflux

          -  Infants presenting intestinal disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvan Vandenplas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Sophie Garreau</last_name>
    <phone>+33(0)155372222</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvan Vandenplas</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 24, 2016</lastchanged_date>
  <firstreceived_date>March 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
